Objective: to develop a multiple-endpoint monitoring system in order to assess and minimize long term risks in hospital nurses exposed to antiblastic drugs. Design: molecular epidemiology study. Setting: S. Orsola-Malpighi Hospital in Bologna, Italy nurses exposed to antiblastic drugs. Participants: 50 exposed subjects (8 males and 42 females) and 50 unexposed individuals (8 males and 42 females) matched for age and smoking habits. Main outcome measures: urinary markers of exposure; Heat Shock Proteins (HSPs) 27, 70, 90, 110; immunological biomarkers in peripheral blood lymphocytes; apoptosis, cell-cycle analysis G1-S-G, typization of Natural Killer cells (NK) and receptors for IL-2 in peripheral blood lymphocytes; micronuclei: frequency in peripheral blood lymphocytes and in exfoliated buccal mucosa cells; activation of specific oncogenes (bax, bcl2, b-actin). Results: 19/50 subjects showed urinary antiblastic drugs levels (3 subjects MTX, 11 subjects CP, 5 subjects MTX and CP). No statistically significant differences were observed in all the considered biomarkers between the exposed and control groups. Conclusion: this biomonitoring study doesn’t evidence any early significant effect associated to the exposure to antiblastic drugs.
Titolo: | BIOMONITORING OF NURSES OCCUPATIONALLY EXPOSED TO ANTINEOPLASTIC DRUGS: THE IMEPA PROJECT |
Autore/i: | Bolognesi C.; NUCCI, MARIA CONCETTA; COLACCI, ANNAMARIA; GRILLI, SANDRO; Ippoliti F.; Mucci N.; Spica V.R.; Barbieri A.; Canitano N.; CHIOZZOTTO, DANIELA; Di Renzo L; Giordano E; HORN, WOLFANGO; Roggieri P.; RISI, ALESSANDRO; SILINGARDI, PAOLA; VACCARI, MONICA; VIOLANTE, FRANCESCO SAVERIO |
Autore/i Unibo: | |
Anno: | 2005 |
Rivista: | |
Abstract: | Objective: to develop a multiple-endpoint monitoring system in order to assess and minimize long term risks in hospital nurses exposed to antiblastic drugs. Design: molecular epidemiology study. Setting: S. Orsola-Malpighi Hospital in Bologna, Italy nurses exposed to antiblastic drugs. Participants: 50 exposed subjects (8 males and 42 females) and 50 unexposed individuals (8 males and 42 females) matched for age and smoking habits. Main outcome measures: urinary markers of exposure; Heat Shock Proteins (HSPs) 27, 70, 90, 110; immunological biomarkers in peripheral blood lymphocytes; apoptosis, cell-cycle analysis G1-S-G, typization of Natural Killer cells (NK) and receptors for IL-2 in peripheral blood lymphocytes; micronuclei: frequency in peripheral blood lymphocytes and in exfoliated buccal mucosa cells; activation of specific oncogenes (bax, bcl2, b-actin). Results: 19/50 subjects showed urinary antiblastic drugs levels (3 subjects MTX, 11 subjects CP, 5 subjects MTX and CP). No statistically significant differences were observed in all the considered biomarkers between the exposed and control groups. Conclusion: this biomonitoring study doesn’t evidence any early significant effect associated to the exposure to antiblastic drugs. |
Data prodotto definitivo in UGOV: | 2006-09-09 17:23:47 |
Appare nelle tipologie: | 1.01 Articolo in rivista |